MannKind posts transcript of Q2 2026 earnings call
MNKD•Q2 2026 earnings call highlights
MannKind discussed Q2 2026 results on an Aug. 5 earnings call attended by CEO Michael Castagna and CFO Chris Prentiss.
- Revenue totaled $109.4 million, up 43% year over year.
- GAAP net loss was $19 million; non-GAAP net loss was $2.7 million.
- Afrezza net sales were $17 million; management cited early pediatric uptake, with over half of dispensed scripts using a cash program.
- Furoscix net sales were $22.2 million, up 43% from Q1 on 49% higher units; gross-to-net adjustments were 29%.
- ReadyFlow will ship in August; $45 million CVR payout is slated for Q3; pro forma cash was $161 million following a $50 million PIPE.
